This article is more than 5 years old. Information may no longer be current.
VIDEO: IBD expert discusses choosing first-line biologic therapies
HONOLULU — After a case-based symposium, Bruce E. Sands, MD, chief of the division of gastroenterology, Icahn School of Medicine at Mount Sinai, New York, discusses his presentation focusing on the question of which biologic therapy to use first in inflammatory bowel disease treatment.
“Now we have a choice between the anti-TNF antibodies and … vedolizumab, which is the first anti-integrin antibody,” Sands said. “It comes down to a lot of small issues related to what we know about the drugs, particular indications for a patient and their concerns for safety. That’s how we, at this point, would choose between these two different biologic categories.”
Disclosure: Sands reports he is a consultant for AbbVie, Janssen and Takeda.